141 related articles for article (PubMed ID: 11021743)
1. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor activity of water-soluble paclitaxel derivatives.
Rose WC; Clark JL; Lee FY; Casazza AM
Cancer Chemother Pharmacol; 1997; 39(6):486-92. PubMed ID: 9118459
[TBL] [Abstract][Full Text] [Related]
3. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacology of BMS-275183, an orally active taxane.
Rose WC; Long BH; Fairchild CR; Lee FY; Kadow JF
Clin Cancer Res; 2001 Jul; 7(7):2016-21. PubMed ID: 11448919
[TBL] [Abstract][Full Text] [Related]
5. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor activity of two novel taxanes.
Rose WC; Fairchild C; Lee FY
Cancer Chemother Pharmacol; 2001; 47(2):97-105. PubMed ID: 11269747
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
9. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
10. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
12. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
[TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration.
Lee E; Kim H; Lee IH; Jon S
J Control Release; 2009 Dec; 140(2):79-85. PubMed ID: 19712714
[TBL] [Abstract][Full Text] [Related]
15. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
17. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
19. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Dykes DJ; Bissery MC; Harrison SD; Waud WR
Invest New Drugs; 1995; 13(1):1-11. PubMed ID: 7499102
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
